Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04929210 · ClinicalTrials.gov registry record · Phase 4

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

A Phase 4 study of Arthritis, Psoriatic, sponsored by Janssen Research & Development.

Active
Registry status
Phase 4
Development phase
411
Enrollment target
20
Study locations

NCT04929210 is a Phase 4 study of Arthritis, Psoriatic that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 411 participants, below the 551-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04929210, a Phase 4 study of Arthritis, Psoriatic, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
411 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

Conditions Studied

Arthritis, Psoriatic

Interventions

  • DRUG Placebo
  • DRUG Guselkumab

Study Locations (20)

Arizona

  • Arizona Arthritis and Rheumatology Research PLLC - Avondale
  • Arizona Arthritis & Rheumatology Research, PLLC - Chandler
  • Arizona Arthritis and Rheumatology Research PLLC - Mesa
  • Arizona Arthritis Research, PLC. - Phoenix
  • Arizona Arthritis and Rheumatology Associates - Sun City
  • Southern Arizona VA Healthcare System - Tucson

California

  • Kaiser Permanent Medical Center - Fontana
  • Newport Huntington Medical Group - Huntington Beach
  • University Of California San Diego - La Jolla
  • Rheumatology Center of San Diego - San Diego

Florida

  • Bay Pines VA Healthcare System - Bay Pines
  • Integral Rheumatology And Immunology Specialists - Plantation
  • Florida Medical Clinic, P.A. - Zephyrhills

Illinois

  • Great Lakes Clinical Trials - Chicago
  • OrthoIllinois - Rockford
  • Willow Rheumatology and Wellness - Willowbrook

Maryland

  • Johns Hopkins Bayview Medical - Baltimore
  • Klein And Associates M D P A - Hagerstown

Arkansas

  • Unity Health-White County Medical Center - Searcy

Connecticut

  • Clinical Research Center of Connecticut - Danbury

Trial Details

FieldValue
Enrollment Target 411 participants
Start Date 2021-08-30
Est. Completion 2027-04-13
Phase Phase 4

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04929210

The ClinicalTrials.gov registry entry for NCT04929210 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 411 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 551-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (25% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04929210 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Arizona, California, Florida.

Frequently Asked Questions

What is clinical trial NCT04929210 about?

NCT04929210 is a clinical study titled "A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease". The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

What is the current status of trial NCT04929210?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 411 participants. The study started on 2021-08-30. Estimated completion is 2027-04-13.

What conditions does trial NCT04929210 study?

This clinical trial studies the following conditions: Arthritis, Psoriatic.

What interventions are being tested in trial NCT04929210?

The interventions under investigation include: Placebo (DRUG), Guselkumab (DRUG).

Who is sponsoring clinical trial NCT04929210?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04929210 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Arthritis, Psoriatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Arthritis, Psoriatic

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.